.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Medtronic
Cerilliant
Deloitte
Chinese Patent Office
Cipla
Mallinckrodt
Covington
Federal Trade Commission

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205513

« Back to Dashboard
NDA 205513 describes CARISOPRODOL, which is a drug marketed by Strides Pharma, Able, Ingenus Pharms Nj, Hikma Intl Pharms, Sandoz, Wilshire Pharms Inc, Watson Labs, Nostrum Labs Inc, Vintage Pharms, Sun Pharm Inds, Sun Pharm Inds Ltd, Sciegen Pharms Inc, Accelrx Labs, Watson Labs Teva, Orient Pharma Co Ltd, Natco Pharma Ltd, Oxford Pharms, Pioneer Pharms, Aurobindo Pharma, Epic Pharma Llc, and Heritage Pharms Inc, and is included in thirty-one NDAs. It is available from fifty suppliers. Additional details are available on the CARISOPRODOL profile page.

The generic ingredient in CARISOPRODOL is aspirin; carisoprodol; codeine phosphate. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; carisoprodol; codeine phosphate profile page.

Summary for NDA: 205513

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Skeletal Muscle Relaxants
Formulation / Manufacturing:see details

Pharmacology for NDA: 205513

Suppliers and Packaging for NDA: 205513

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARISOPRODOL
carisoprodol
TABLET;ORAL 205513 ANDA Vensun Pharmaceuticals, Inc 42543-434 42543-434-01 100 TABLET in 1 BOTTLE (42543-434-01)
CARISOPRODOL
carisoprodol
TABLET;ORAL 205513 ANDA Vensun Pharmaceuticals, Inc 42543-434 42543-434-05 500 TABLET in 1 BOTTLE (42543-434-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Nov 12, 2015TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength350MG
Approval Date:Nov 12, 2015TE:AARLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Fuji
Express Scripts
Queensland Health
Chinese Patent Office
Johnson and Johnson
US Department of Justice
Novartis
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot